Clinical Trial

A Retrospective Real-World Study Based on RATIONALE-307

Recruiting
View on ClinicalTrials.gov →
Summary
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-03-27
Trial Details
NCT Number NCT07478809
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions NSCLC (Advanced Non-small Cell Lung Cancer)
Enrollment 109 participants
Start Date 2026-02-28
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-27